GRI Bio has announced positive topline results from its phase 2a clinical trial evaluating GRI-0621 in idiopathic pulmonary ...
Genfit has announced encouraging preliminary results from its phase 1b clinical trial evaluating investigational drug GNS561 in combination with a MEK inhibitor (MEKi) in patients with KRAS mutated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback